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Introduction
Population-based data supplied by cancer registries have in-
creasingly attracted attention, provided that valid information on 
clinical and pathological findings, therapies, follow-up and long-
term results are available. With these data, regional cancer care can 
be presented with total transparency. This transparency ranges 
from knowledge about the variability of initial examination find-
ings to the variability of treatments and the question whether ther-
apies are applied in agreement with guidelines that in general rep-
resent the best-proved evidence. It should be pointed out explicitly 
that cancer registries with their collection of prospectively surveyed 
cohorts can reach level 2 of evidence, close behind randomised 
clinical trials (RCTs) [1].
Therefore results of cancer registry studies can be meaningful 
and pose innovative questions in cases of treatment options when 
level 1 evidence (RCTs) does not exist for specific groups of pa-
tients. Furthermore, health care providers should regularly be given 
feedback about the actuality and variability of their treatment in 
comparison to a wider environment, e.g. the total catchment area of 
the cancer registry. Significant deviations can be revealed and com-
municated. In addition, cancer registry data can show to what ex-
tent results of RCTs can be realised in the general population and 
which subgroups may not benefit from treatment improvements. 
Comparisons with national and international data contribute to 
valid ascertainment [2]. Results over time are interesting with re-
gard to quality assurance and can give incentives for clinical science 
[2]. Transparency of regional health care results can be offered con-
temporarily on the Internet [3–5]. Prostate cancer as the most com-
mon cancer of men in the USA [3] and in Germany [4] and the 
second most common cancer of men after lung cancer in the world 
[5] exemplifies the value of registry data for understanding progress 
in the detection and treatment of cancer over decades.
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Summary
Background: The study objective was to examine 
changes in prognosis and treatment of prostate cancer 
patients over 20 years and to evaluate their impact on 
survival. Patients and Methods: 38,861 prostate can-
cer patients diagnosed between 1990 and 2010 and liv-
ing in the catchment area of the Munich Cancer Registry 
were analysed. Results: Pre-therapeutic prostate-spe-
cific antigen (PSA) testing increased substantially in the 
early 1990s. A shift from capsule-exceeding tumours to 
capsule-limited tumours also took place especially in the 
1990s. The proportion of radical prostatectomy increased 
continuously over the last 20 years from 20% to almost 
50% whereas hormone therapy decreased from 55% to 
18%. Radiation therapy and transurethral resection of 
the prostate increased slightly from about 5% to 10%. 
The 5- and 10-year relative survival rates increased from 
92% to 97% and from 86% to 92%, respectively. Conclu-
sions: 2 reasons may account for the rise in survival 
rates over 20 years: First, the establishment of widely 
used PSA testing resulted in a shift towards more fa-
vourable T categories due to the detection of many ad-
ditional small tumours as well as the noticeable change 
in initial treatment strategy towards more radical prosta-
tectomies. The second factor that likely increased sur-
vival was improvements in the therapies themselves.
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Patients and Methods
Data Collection
The Munich Cancer Registry (MCR) is the population-based clinical 
cancer registry of Upper Bavaria and parts of Lower Bavaria (Southern Ger-
many). Its catchment area has been enlarged stepwise from 2.3 million to 4.6 
million inhabitants in 2007 [6, 7]. Pathologic reports of solid tumours are 
available from all pathology laboratories in this area. From these reports, the 
number of prostate cancer patients in the region is systematically obtained. 
In addition, data about disease characteristics as histology, tumour/node/
metastasis (TNM) stage, prostate-specific antigen (PSA), Gleason score and 
therapy are prospectively collected from MCR-affiliated hospitals. Life status 
is systematically maintained by both information from the clinicians and 
death certificates. Thus, active follow-up data are available for about 95% of 
cases.
Patients
A total of 46,797 patients diagnosed with malignant tumours of the prostate 
and living within the catchment area were registered prospectively over 2 dec-
ades from 1990 to 2010. Patients with evidence of lymphoma or sarcoma, those 
with registration by death certificate only (DCO) and patients with previous or 
synchronous malignant tumours were excluded. Thus, time-trend analyses 
were performed on the epidemiological cohort of 38,861 patients with prostate 
cancer as the first malignant tumour. All survival analyses are based on 36,530 
patients with an active follow-up (fig. 1).
Statistical Analysis
The MCR organises data in an Oracle database. Statistical analyses were run 
in SAS (Statistical Analysis System v. 9.2). The percentages of the presented 
subcategories are related to the sum of each item with available data; missing 
values are not taken into account. Overall survival (OS) was estimated by the 
Kaplan-Meier method. Differences in subgroups were tested by the log-rank 
test. Relative survival (RS) was computed by the ratio of the observed survival 
rate to the expected survival rate. The expected survival time of age-matched 
male individuals was calculated from life tables of the general German popula-
tion. The significance level in all analyses was set at 5%. The study period was 
divided into 4 intervals (1990–1994, 1995–1999, 2000–2004, 2005–2010) to de-
scribe trends in patient characteristics and survival.
Results
Incidence
In the first 3 years of the study period (1990–1992) a crude inci-
dence rate (CIR) of 55.0 per 100,000 is measured. Converted into 
the European (ASR(EU)) or the world age-standardised rate 
(ASR(W)) according to Segi, an incidence rate of 55.2 or 35.9, re-
spectively, is observed per 100,000. In the last 3 years (2008–2010), 
the CIR is 106.0 per 100,000 (ASR(EU): 78.6, ASR(W): 53.8). Thus, 
the incidence rates increased noticeably during the selected study 
period, regardless of the applied standard.
The patient characteristics and prognostic parameters by period 
are presented in table 1.
Age at Diagnosis
The age distribution stays stable over 2 decades. The median age 
is about 69 years. The 25% and 75% percentiles are 64 and 75 years 
and the 10% and 90% percentiles are 58 and 80 years. At initial di-
agnosis, every 10th man is older than 80 years.
T Category
Figure 2A presents the distribution of the T category over time. 
T is a combination of pT and cT, if pT is not available. The propor-
tion of T1 rises from 14% in the year 2001 to 32% in 2010. The 
proportion of T2 tumours more than doubles from 25% in 1992 to 
61% in 1998. Stable for 5 years since 2004, it decreases inversely to 
the development of T1. The proportions of T3 and T4 tumours de-
velop inversely compared to T2. The T3 proportion decreases from 
50% in 1992 to 15% in 2006, now again increasing to 22% in 2010. 
In contrast, the proportion of T4 decreases from 12% in 1990 to 2% 
in 2010.
Prostate-Specific Antigen
Figure 2B shows the distribution of the PSA values available 
since 1994. The lowest category (< 4 ng/ml) remains stable between 
11 and 15%. The proportion of PSA values of 4 to < 10 ng/ml in-
creases from a rate of 29% up to 52%. The 2 highest categories de-
crease simultaneously from about 30% to 20%. Overall, a shift to-
wards lower PSA values has taken place.
Gleason Score
This marker presented in figure 2C is well documented since 
1998. In the time-trend analysis, the decrease of the proportions of 
the 2 lowest categories is most noticeable. Score 2–4 decreases from 
10% to 1% and score 5–6 is reduced from 46% to 32%. Inversely 
score 7 doubles in proportion from 21% to 43%. The highest score 
(8–10) fluctuates around a rate of 22%. Thus, the distribution of 
the Gleason score has shifted towards higher scores.
Initial Treatment
As presented in figure 2D, the proportion of radical prostatecto-
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Fig. 1. Flow chart of 
the patient cohort 
1990–2010. PIN = Pro-
static intraepithelial 
neoplasia, CIS = carci-
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use of radical prostatectomy as an initial treatment is highly corre-
lated with the number of capsule-remaining tumours (Pearson’s r 
= 0.88). The use of hormone therapy experienced a major decline. 
Starting at a rate of 55% in 1990, it accounts for 17% in 2010. Both 
transurethral resection of the prostate and radiotherapy showed a 




























































































































































































































































c/pT1 c/pT2 pT2 c/pT3 pT3 c/pT4 pT4
Fig. 2. Changes over time in (A) c/pT and pT 
category, (B) PSA category, (C) Gleason score,  
(D) initial treatment. RPE = Radical prostatectomy,  
TUR = transurethral resection, XRT = radiation 




































Fig. 3. Survival by year of initial diagnosis  
(n = 36,530). (A) Overall (p < 0.0001), (B) relative.
Fig. 4. PPS from distant metastasis by year of 
 diagnosis of metastasis for (A) primary M0 (n = 
1,796, p = 0.2240), (B) primary M1 (n = 2,108,  
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Table 1. Prognostic parameters by year of diagnosis
  Year of diagnosis
  1990–1994 1995–1999 2000–2004 2005–2010 All
  N % N % N % N % N %
All 3,725 100.0 7,154 100.0 12,527 100.0 15,455 100.0 38,861 100.0
Age
Median, years 69.8   68.5   68.0   68.9   68.6  
< 50 38 1.0 72 1.0 137 1.1 226 1.5 473 1.2
50–54 156 4.2 260 3.6 427 3.4 522 3.4 1,365 3.5
55–59 339 9.1 874 12.2 1,279 10.2 1,298 8.4 3,790 9.8
60–64 554 14.9 1,264 17.7 2,650 21.2 2,450 15.9 6,918 17.8
65–69 801 21.5 1,596 22.3 2,832 22.6 4,187 27.1 9,416 24.2
70–74 752 20.2 1,431 20.0 2,447 19.5 3,382 21.9 8,012 20.6
≥ 74 1,085 29.1 1,657 23.2 2,755 22.0 3,390 21.9 8,887 22.9
c/pT categorya                    
T1 501 16.4 942 17.0 1,894 19.4 3,356 27.5 6,693 21.9
T2 988 32.3 2,981 53.8 5,751 58.8 6,280 51.4 16,000 52.3
T3 1,270 41.5 1,309 23.6 1,812 18.5 2,204 18.0 6,595 21.5
T4 304 9.9 313 5.6 320 3.3 379 3.1 1,316 4.3
Missingb 662 17.8 1,609 22.5 2,750 22.0 3,236 20.9 8,257 21.2
cT category                    
T1 545 19.5 1,057 21.2 2,130 27.0 3,694 49.2 7,426 32.0
T2 863 30.8 2,617 52.5 4,300 54.5 2,873 38.2 10,653 45.9
T3 1,125 40.2 1,059 21.3 1,194 15.1 704 9.4 4,082 17.6
T4 268 9.6 250 5.0 264 3.3 242 3.2 1,024 4.4
Missingb 924 24.8 2,171 30.3 4,639 37.0 7,942 51.4 15,676 40.3
pT category                    
T2 711 35.8 2,255 60.3 4,581 70.3 6,075 68.3 13,622 64.5
T3 1,095 55.2 1,264 33.8 1,719 26.4 2,537 28.5 6,615 31.3
T4 179 9.0 223 6.0 212 3.3 277 3.1 891 4.2
Missingb 1,740 46.7 3,412 47.7 6,015 48.0 6,566 42.5 17,733 45.6
Metastasis status                    
M0 3,412 91.6 6,752 94.4 11,926 95.2 14,549 94.1 36,639 94.3
M1 313 8.4 402 5.6 601 4.8 906 5.9 2,222 5.7
Missingb 621 16.7 1,734 24.2 3,363 26.8 4,022 26.0 9,740 25.1
Lymph node status                
N+ 202 5.4 198 2.8 326 2.6 722 4.7 1,448 3.7
N0 1,515 40.7 2,583 36.1 5,233 41.8 7,426 48.0 16,757 43.1
NX 1,387 37.2 2,639 36.9 3,605 28.8 3,285 21.3 10,916 28.1
PSA value                
Median, ng/ml 14.0   10.2   8.4   7.8   8.5  
≤ 4 222 16.1 587 12.3 1,142 13.2 1,608 13.9 3,559 13.5
> 4–10 325 23.5 1,785 37.4 4,017 46.5 5,676 49.2 11,803 44.8
> 10–20 330 23.9 1,194 25.0 1,889 21.9 2,165 18.8 5,578 21.2
> 20 505 36.5 1,212 25.4 1,589 18.4 2,089 18.1 5,395 20.5
Missingb 2,343 62.9 2,376 33.2 3,890 31.1 3,917 25.3 12,526 32.2
Gleason score                    
2–4 5 16.1 76 8.6 752 6.6 459 3.1 1,292 4.8
5–6 4 12.9 367 41.8 4,961 43.4 5,440 37.0 10,772 39.8
7 4 12.9 228 25.9 3,604 31.5 5,600 38.1 9,436 34.9
8–10 18 58.1 208 23.7 2,115 18.5 3,204 21.8 5,545 20.5
Missingb 3,694 99.2 6,275 87.7 1,095 8.7 752 4.9 11,816 30.4
PSA = Prostate-specific antigen.
ac/pT category = a combination of pT and cT; if pT is not available (e.g. no surgery), cT is inserted.
bThe percentage of the subcategories is related to the sum of each item with available data; missing values are not taken into account.
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Survival
Figure 3A, B presents OS and RS curves stratified by time peri-
ods. In 1990–1994, the 5- and 10-year OS and RS rates were 72.0% 
and 50.9% and 92.5% and 84.9%, respectively. Survival improves 
continuously with 5-year OS and RS rates of 80.7% and 94.7%, re-
spectively, in 2005–2010 and 10-year OS and RS rates of 62.9% and 
91.3%, respectively, in 2000–2004.
Post-progression survival (PPS) from diagnosis of distant me-
tastasis is presented in Figure 4A, B for primary M0 and M1 pa-
tients. In both subgroups, no essential improvement can be seen 
within the last 20 years. Primary M0 patients have a median PPS of 
about 1.3 years, primary M1 patients of about 2.4 years.
Discussion
This German study population shows a lower incidence level of 
prostate cancer compared to Germany in general and other indus-
trialised countries [4, 5], probably due to underreporting in outpa-
tient care. The rise in the incidence rate over time, however, is 
comparable. A detailed view on the incidence rate reveals that the 
rise affects T1 and, most notably, T2 tumours in the 1990s (c/pT 
and pT), while the incidence of advanced capsule-penetrating tu-
mours stays low and stable over time. Similar differences are seen 
between the screening and non-screening cohorts in the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) [8]. 
Compendiously, the numbers of detected tumours correlate mod-
erately with the numbers of PSA tests [9]. Altogether, this sup-
ports the assumption that the broad use of PSA tests starting in the 
1990s in Europe has led to the augmented additional detection of 
many small tumours [10–12]. Presumably, this may be the main 
reason for the observed stage shift from capsule-penetrating to 
capsule-remaining tumours. It is most unlikely that this stage shift 
is caused purely by today’s early detection of formerly advanced 
tumours.
The shift of the PSA distribution towards lower values may also 
be caused by the increased use of PSA tests [9, 10].
The changes of the Gleason score distribution may reproduce 
newly made modifications and recommendations in the grading 
system. Nowadays, a Gleason score of 2 is categorised as adenosis 
(atypical adenomatous hyperplasia) rather than adenocarcinoma. 
A score of 2–4 should not be assigned to a definite grade by needle 
biopsy only, due to problems of reproducibility and the danger of 
underestimating the dignity of the tumour [13, 14]. The category 
shift from Gleason score 5–6 to 7 can be the result of modifications 
in the grading system in 2005 when some cell structures were cate-
gorised into higher Gleason grades. Additionally, a different deri-
vation of the Gleason score on biopsies – adding the most common 
and the highest Gleason pattern instead of adding the most com-
mon and the second most common pattern – can also lead to the 
observed changes [15]. Further changes in the Gleason score distri-
bution may be expected due to the update in 2010 when again 
some cell structures were assigned to higher Gleason grades [16].
Thus, the contradictive behaviour of the PSA distribution (drift-
ing towards lower values) and the Gleason score distribution (drift-
ing towards higher scores) may be plausible.
The use of radical prostatectomy as an initial treatment is highly 
correlated with the number of capsule-remaining tumours. This 
might indicate that the observed change of treatment to more sur-
gical therapy depends less on improvements in practice but more 
on the increased number of PSA-detected localised tumours with 
the option of curative radical prostatectomy [13, 14]. Overall, 
changes in prognostic parameters are accompanied by changes in 
therapeutic parameters (table 2).
The improvement in the 5- and 10-year RS by about 6 percent 
units can also be seen in other German population cohorts [17]. 
  Year of diagnosis
  1990–1994 1995–1999 2000–2004 2005–2010 All
  n % n % n % n % n %
All 3,725 100.0 7,154 100.0 12,527 100.0 15,455 100.0 38,861 100.0
Initial treatment                    
RPE 976 30.4 2,556 43.7 4,664 44.9 6,799 53.5 14,995 46.6
TUR 210 6.5 561 9.6 913 8.8 1,363 10.7 3,047 9.5
HIFU     107 1.8 251 2.4 154 1.2 512 1.6
XRT 250 7.8 483 8.3 1,202 11.6 1,347 10.6 3,282 10.2
Hormone 1,739 54.1 2,037 34.8 3,040 29.3 2,674 21.0 9,490 29.5
Chemo 16 0.5 27 0.5 64 0.6 65 0.5 172 0.5
Drug         3 0.0 11 0.1 14 0.0
AS and WW 22 0.7 76 1.3 245 2.4 292 2.3 635 2.0
Missinga 512 13.7 1,307 18.3 2,145 17.1 2,750 17.8 6,714 17.3
RPE = Radical prostatectomy, TUR = transurethral resection of the prostate, HIFU = high-intensity focused ultrasound,  
XRT = radiation therapy, Hormone = hormone therapy, Chemo = chemotherapy, Drug = medical treatment, AS = active surveillance, 
WW = watchful waiting.
aThe percentage of the subcategories is related to the sum of each item with available data; missing values are not taken into account.
Table 2. Therapeutic 
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These authors also conclude that the survival improvement might 
be attributable to the shift to more localised tumours due to the 
increased use of PSA screening. Also treatment improvements may 
have an influence on better survival. Analyses stratified by time pe-
riod and T category show an improvement in cancer-specific sur-
vival in stages T1 and T2, and also in stages T3 and T4 after prosta-
tectomy. A 3-percentage point better tumour-specific 12-year sur-
vival was found in a study that compared radical prostatectomy 
and observation in 1994–2002: 95.6% versus 92.6% [18]. In cases of 
such good prognosis, this 3-percentage point improvement seems 
small, but relatively it amounts to about 40%. Such stage-specific 
improvements can be a hint at partial treatment improvements 
[19–21].
The prostate cancer survival in the MCR catchment area is 
comparable or even slightly better than in other German and Euro-
pean regions, as recently published by the European Cancer Regis-
try (EUROCARE)-5 study [22]. The MCR 5-year RS rate is 95.9% 
(95% confidence interval (CI): 95.2–96.6%) compared to the Ger-
many mean of 89.4% (95% CI: 88.8–89.9%) and the European 
mean of 83.4% (95% CI: 83.1–83.6%).
There may be a good chance that the observed stagnation in the 
PPS may be overcome in the near future when newly developed 
and approved agents keep their promises in metastatic castration-
resistant prostate cancer [23].
In summary, 2 reasons may account for the rise in survival rates 
over the last 20 years: First, the establishment of widely used PSA 
testing resulted in a shift towards more favourable T categories due 
to the detection of many additional small tumours, and a noticea-
ble change in initial treatment strategy towards more radical pros-
tatectomies, which by itself may partially be the result of the T cat-
egory shift. The second reason may be improvements in the ap-
plied therapies themselves.
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